Home›Research›Compare›ARA-290 vs MOTS-c
Peptide ComparisonARA-290 vs MOTS-c
Both are Longevity & Cellular peptides.
ARA-290
Cibinetide
Half-life: ~2 min (IV); ~10–20 min (SC)
16 providers listed
MOTS-c
Mitochondrial ORF of the 12S rRNA type-c
Half-life: Unknown (rapidly cleared from plasma)
181 providers listed
ARA-290 carries stronger published evidence (RCT, 3 key studies) than MOTS-c (Cohort study, 19); both are research compounds.
ARA-290
Evidence
Half-life
~2 min (IV); ~10–20 min (SC)
MOTS-c
Evidence
Half-life
Unknown (rapidly cleared from plasma)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | ARA-290 |
| Further along in FDA review | ARA-290 |
| Lower typical price per mg | ARA-290 |
| More provider options (16 vs 181) | MOTS-c |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
ARA-290
MOTS-c
ARA-290
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.
Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients
ARA 290, a non-hematopoietic erythropoietin analogue, improves metabolic control and neuropathic symptoms in…
MOTS-c
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resis…
LAT1-mediated delivery of engineered R13A-MOTS-c attenuates radiation-induced lung injury via Nrf2 activation…
Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercis…
Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human me…
+15 more
About ARA-290
Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing
About MOTS-c
Mitochondria-derived peptide that translocates to nucleus under stress; activates AMPK pathway, regulates AICAR and folate-methionine cycle
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
ARA-290
No established clinical contraindications
MOTS-c
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
ARA-290
MOTS-c
Where to source these peptides
ARA-290
16 listed
Browse directory →
Providers offeringMOTS-c
181 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 22, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). ARA-290 vs MOTS-c — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/ara-290/mots-c